Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.…
Alumis (ALMS) Stock Fair Value Moves Lower After Mixed Analyst Views On LUMUS
Alumis (NASDAQ: ALMS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 251 employees.
The shares were at 3.960 USD on 20 November 2026, down 16.1% over 52 weeks. Its 52-week range is 3.935 USD to 30.77 USD, and it trades at the bottom of that range.
Its market capitalisation is 514.09M USD.
Alumis reports return on equity of -80.8% and revenue down 7.7% year over year.
It holds more cash than debt, a net cash position of 396.03M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.